Clinical Trials · NCT04777396
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,840
- Start date
- May 2021
- Locations
- 444 sites, 37 countries
- Primary endpoint
- Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score